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PsychosocialVagus nerve stimulation (VNS) is awidely used adjunctive treatment option for intractable epilepsy.Most studies
have demonstrated short-term seizure outcomes, usually for up to 5 years, and thus far, none have reported psy-
chosocial outcomes in adults. We aimed to assess long-term seizure and psychosocial outcomes in patients with
intractable epilepsy on VNS therapy formore than 15 years.We identiﬁedpatientswhohadVNS implantation for
treatment of intractable epilepsy from 1997 to 2013 at our Comprehensive Epilepsy Program and gathered de-
mographics including age at epilepsy onset and VNS implantation, epilepsy type, number of antiepilepsy drugs
(AEDs) and seizure frequency before VNS implantation and at the last clinic visit, and themost recent stimulation
parameters from electronic medical records (EMR). Phone surveys were conducted by research assistants from
May to November 2014 to determine patients' current seizure frequency and psychosocial metrics, including
driving, employment status, and use of antidepressants. Seizure outcomes were based on modiﬁed Engel classi-
ﬁcation (I: seizure-free/rare simple partial seizures; II: N90% seizure reduction (SR), III: 50–90% SR, IV: b50% SR;
classes I to III (N50% SR)= favorable outcome). A total of 207 patients underwent VNS implantation, 15 ofwhom
were deceased at the time of the phone survey, and 40 had incomplete data for medical abstraction. Of the re-
maining 152, 90 (59%) were contacted and completed the survey. Of these, 51% were male, with the mean age
at epilepsy onset of 9.4 years (range: birth to 60 years). There were 35 (39%) patients with extratemporal epilep-
sy, 19 (21%) with temporal, 18 (20%) with symptomatic generalized, 5 (6%) with idiopathic generalized, and
13 (14%) with multiple types. Final VNS settings showed 16 (18%) patients with an output current N2 mA and
14 (16%) with rapid cycling. Of the 80 patients with seizure frequency information, 16 (20%) had a modiﬁed
Engel class I outcome, 14 (18%) had class II, 24 (30%) had class III, and 26 (33%) had class IV. Eighty percent
said having VNSwasworthwhile. Among the 90 patients, 43 patientswere ≥18 years oldwithout developmental
delay in whom psychosocial outcomes were further analyzed. There was a decrease in the number of patients
driving (31% vs 14%, p = 0.052) and working (44% vs 35%, p = 0.285) and an increase in the number of patients
using antidepressant medication (14% vs 28%, p = 0.057) at the time of survey compared to before VNS. In this
subset, patients with N50% SR (60%) were taking signiﬁcantly fewer AEDs at the time of survey compared to pa-
tients with unfavorable outcomes (median: 3 vs 4, p=0.045). The associations of N50% SRwith the psychosocial
outcomes of driving, employment, and antidepressant use were not signiﬁcant, although 77% of this subset said
VNS was worthwhile.
This is the ﬁrst study that assesses both seizure and psychosocial outcomes, and demonstrates favorable seizure
outcomes of N50% SR in 68% of patients and seizure freedom in 20% of patients. A largemajority of patients (80%)
considered VNS therapy worthwhile regardless of epilepsy type and psychosocial outcomes.
© 2015 Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).sy Program, Department of
Boulevard, Detroit, MI 48202,
icle under the CC BY-NC-ND license (1. Introduction
Almost 30% of all epilepsies remain intractable to antiepilepsy drugs
(AEDs) [1], and adjunct nonpharmacologic therapies that include surgi-
cal treatment options, stimulation therapies, and ketogenic or alterna-
tive medical therapies are often explored in those cases. Since 1997,
VNS (by VNS Therapy Systems, Cyberonics, Inc., Houston, TX, USA) has
been approved by the U.S. Food and Drug Administration (FDA) as anhttp://creativecommons.org/licenses/by-nc-nd/4.0/).
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efﬁcacy has been established through a randomized controlled trial [2].
Subsequent studies have reported seizure outcomes for up to 5 years
[3–7] and rarely to 10–11 years [8,9]. A few studies have assessed
behavioral and cognitive outcomes after VNS therapy in children [10]
and the effect on mood in adults [11]. However, thus far, no data
assessing common psychosocial outcomes are available in adults. The
aim of our study was to assess long-term seizure and psychosocial out-
comes for more than 15 years in all patients with intractable epilepsy
whohad VNS implantation at our tertiary epilepsy center by conducting
follow-upphone surveys. This studywas, to some extent, a continuation
of the assessment of long-term outcomes of surgical therapies for in-
tractable epilepsy at our center [12].2. Materials and methods
2.1. Study description, approvals and consents
This was a retrospective study on patients with intractable epilepsy to
gather pre-VNS implantation information and a cross-sectional study to
assess postimplantation seizure and psychosocial outcomes. Patients
who had VNS implantation for intractable epilepsy from 1997 to 2013
were retrospectively identiﬁed. Data were collected usingmedical record
chart reviews and phone surveys. Low-risk, retrospective methodologies
of the chart review led to waiving of written consents. Prior to starting
every phone survey, verbal consents were obtained. This study was ap-
proved by the Henry Ford Health System Institutional Review Board
(IRB # 8835).Table 1
Seizure outcomes bymodiﬁed Engel classiﬁcation for 80 patients with intractable epilepsy
on VNS therapy.
Class Modiﬁed Engel description Number (%)
I Seizure-free
Rare, nondisabling simple partial seizures
16 (20%)
II N90% reduction in seizure frequency
Rare complex partial seizures
14 (18%)
III 50–90% reduction in seizure frequency 24 (30%)
IV b50% reduction in seizure frequency 26 (33%)2.2. Data collection
Demographic information consisting of gender, age and race, age at
epilepsy onset and VNS implantation, epilepsy type, number of AEDs
used, and seizure frequency before VNS implantation were collected
by retrospective chart reviews using the EMR. Clinical notes from the
last visit in EMR were reviewed to obtain information on the most re-
cent seizure frequency and stimulation parameters. The Department
of Public Health Sciences obtained patient contact information from
EMR or through a public search database. The research assistants (KM,
AG) attempted follow-up phone surveys for all the patients from May
to November 2014. A script that included conﬁdentiality statements
along with questions about the patients' current seizure frequency,
the current number of AEDs being taken, and queries on psychosocial
metrics was followed by the research assistants during the phone sur-
vey. In our experience, phone surveys had a potential for a better re-
sponse rate, especially given that a number of the patients may have
moved out of the area and/or were not receiving their care at our insti-
tution, and hence were chosen over mailed or in-person surveys. The
selection of the psychosocial metrics of driving, employment, and anti-
depressant use were chosen as by Dupont et al. [13] and was also based
on our experiencewith patientswith epilepsy demonstrated in postsur-
gical outcomes [12]. Patients who were deceased at the time of survey
and those who refused to participate or could not be contacted despite
at least three phone attempts were not included in the ﬁnal outcome
assessment.
We aimed to assess the effect of some VNS stimulation parame-
ters on the therapeutic response [14] by assessing seizure outcomes.
We considered current stimulation of more than 2 mA as a cutoff for
higher intensities as a lower current was safer and better tolerated
[15], as in our clinical experience. Duty cycle was calculated (ON
time + 4/ON time + OFF time) for each of the VNS settings and the
ratio of more than 25% was considered as rapid cycling in our
study, as duty cycles of 50% or less are typically known to be safe
and effective [14].2.3. Outcome assessment
Seizure outcomes after VNS implantation were based on modiﬁed
Engel classiﬁcation [16], and classes I to III were considered as favorable
outcomeswith SR of N50% (Table 1). This classiﬁcationwas based on the
patients' responses to questioning about seizure frequency at the time
of survey compared to before VNS implantation. Psychosocial metrics
assessed on the phone survey included driving status, employment sta-
tus (full-time, part-time, or unemployed) and the use of antidepressant
medications before VNS and at the time of survey. Patients' satisfaction
was assessed by asking them if it was worthwhile having VNS as an ad-
junctive treatment for intractable epilepsy.
2.4. Statistical analysis
To assess the associations of survey response, epilepsy type, and fa-
vorable outcomeswith demographics, VNS stimulation parameters, and
psychosocialmeasures, chi-square testswere used for the binary or cat-
egorical variables, two-sample t-tests were used for the continuous
measures of age at onset and age at VNS implantation, and Wilcoxon
two-sample tests were used for number of years between epilepsy
onset and VNS implantation, number of seizures per month before
VNS, number of AEDs before VNS, and duration of VNS therapy.
McNemar's tests were done to compare preoperative to postoperative
responses for driving, employment, and use of antidepressants. Statisti-
cal signiﬁcance was set at the 0.05 level. Statistical analyses were per-
formed using SAS version 9.2.
3. Results
3.1. Description of identiﬁed patients
A total of 207 patients with epilepsy were identiﬁed as having VNS
implantation between 1997 and 2013. Fifteen patients were conﬁrmed
to be deceased, and 40 had incomplete data for medical abstraction. Of
the remaining 152 patients, 90 (59%) were contacted and agreed to
complete the phone survey, 14 (9%) refused to participate, and
48 (32%) of the patients could not be contacted (21 with wrong or no
phone numbers, 22 with no answer, and 5 repeatedly postponed an-
swering the survey) after at least three attempts on different days and
different times. Ten patients could not have modiﬁed Engel classiﬁca-
tions because of missing information for frequency of seizures prior to
VNS or at the time of the survey. Of the 152 eligible patients, 53%
(n = 80) were male, 100 (66%) were Caucasian, and 15 (10%) were
African American. The mean age at epilepsy onset was 9.7 years
(range: birth to 60 years). The mean duration of epilepsy before VNS
was 20.5 years (range: 3 to 54 years).
3.2. Medical record and survey
Comparisons of demographic, medical, and surgical variables
between patients with and without completed surveys were performed
in order to assess any potential responder bias (Table 2). No differences
were detected for gender, race, age at epilepsy onset, age at VNS implan-
tation, duration between epilepsy onset and VNS implantation, presence
Table 2
Comparison of patients who did and did not complete the survey.
Variable Response Survey completed
(N = 90)
No survey
(N = 62)
p-Value
Gender F 44 (49%) 28 (45%) 0.651
M 46 (51%) 34 (55%)
Race African American 6 (7%) 9 (15%) 0.448
Caucasian 62 (69%) 38 (61%)
Other 5 (6%) 3 (5%)
Unknown 17 (19%) 12 (19%)
Age at epilepsy onset Mean ± S.D. 9.4 ± 11.9 10.3 ± 12.1 0.669
Median (range) 5 (0 to 60) 4.5 (0 to 41)
Age at VNS Mean ± S.D. 31.1 ± 14.1 31.2 ± 15.0 0.964
Median (range) 30.5 (5 to 65) 33 (4 to 67)
Years between epilepsy onset and VNS implantation Mean ± S.D. 20.7 ± 12.7 20.2 ± 10.4 0.938
Median (range) 18 (3 to 54) 17.5 (4 to 41.33)
Developmental delay Yes 44 (49%) 31 (51%) 0.816
No 46 (51%) 30 (49%)
Presence of status epilepticus before VNS Yes 13 (15%) 7 (12%) 0.587
No 75 (85%) 53 (88%)
Resective epilepsy surgery performed Yes 28 (31%) 10 (17%) 0.052
No 62 (69%) 49 (83%)
Number of seizures per month before VNS Mean ± S.D. 50.9 ± 108.2 166.7 ± 514.9 0.129
Median (range) 12.75 (0.33 to 600) 17.5 (1 to 3600)
Number of AEDs before VNS Mean ± S.D. 3.0 ± 1.0 2.8 ± 1.1 0.207
Median (range) 3 (0 to 5) 3 (0 to 8)
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zure frequency, and number of AEDs used before VNS between the two
groups. Only prior resective epilepsy surgery showed a trend with pa-
tients who completed the survey having a higher rate of prior surgeries
compared to patients who did not (31% vs 17%, p= 0.052). Also, the dif-
ferences betweenpatientswhodid anddid not complete the surveywere
not signiﬁcant for epilepsy classiﬁcation (Table 3), duration of VNS ther-
apy (Table 4), and stimulation parameters at the last VNS setting docu-
mented in EMR (Table 5).
3.3. Survey responses
For those patientswho completed the survey, the average age at sur-
vey was 39 years (range: 8 to 70 years). The median duration of VNS
therapy was 7 years (range: 0 to 16 years) with 36% (n = 33) being
10 or more years. The vast majority (92%) of the patients were still re-
ceiving VNS therapy. Themedian number of AEDs at the time of the sur-
veywas 3 (range: 0 to 8). Twenty-ﬁve (28%) patients had experienced a
VNS complication. However, 72 (80%) considered the VNS implantation
worthwhile.
3.4. Favorable outcomes
Among the 90 patients with surveys, 10 had insufﬁcient informa-
tion to compute the modiﬁed Engel class. Seizure frequency was
missing for 7 patients from the survey, 2 from before VNS and 1
from both time points. For the remaining 80 patients, 16 (20%) had
class I (seizure-free), 14 (18%) had class II (N90% SR), 24 (30%) hadTable 3
Survey and seizure outcomes by epilepsy classiﬁcation.
Epilepsy classiﬁcation No survey
(N = 62)
N (%)
Survey completed
(N = 90)
N (%)
Favorable outcome
(N50% SR)
N (%)a
Idiopathic generalized 3 (5%) 5 (6%) 3 (75%)
Symptomatic generalized 10 (16%) 18 (20%) 10 (59%)
Temporal partial 17 (27%) 19 (21%) 15 (88%)
Extratemporal partial 22 (35%) 35 (39%) 21 (72%)
Multiple types 10 (16%) 13 (14%) 5 (38%)
p-Values 0.888 0.053
a Percentage of surveyedpatientswith seizure information (IG: n=4, SG: n=17, TP: n=
17, ETP: n = 29, and multiple types: n = 13).class III (50–90% SR), and 26 (33%) had class IV (b50% SR) outcomes.
A favorable outcome, deﬁned as more than 50% reduction in seizure
frequency, was associated with a lower output current (≤2 mA: 73%
vs N2mA: 42%, p= 0.03, Table 5). The association of N50% SR and ep-
ilepsy classiﬁcation showed a trend (p = 0.053, Table 3) with 88% of
patients with temporal lobe epilepsy having the highest rate of fa-
vorable seizure outcomes while 38% of patients with multiple types
had the lowest rate. The associations of N50% SR with age at survey,
gender, race, age at epilepsy onset, age at VNS, duration between ep-
ilepsy onset and VNS implantation, presence of developmental delay,
presence of status epilepticus before VNS, seizure frequency before
VNS, number of AEDs used before VNS, and resective epilepsy sur-
gery were not signiﬁcant.
3.5. Psychosocial outcomes
Among the 90 patients, 43 patients were ≥18 years old at VNS im-
plantation without developmental delay in whom psychosocial out-
comes were further analyzed. There was a decrease in the number of
patients driving (31% vs 14%, p = 0.052) and working (44% vs 35%,
p = 0.285) and an increase in the number of patients using antidepres-
santmedication (14% vs 28%, p=0.057) at the time of survey compared
to before VNS.
3.6. Psychosocial metrics and favorable seizure outcomes
In the subset of 43 patients who were adults at the time of VNS im-
plantation and had no developmental delays, 35 had modiﬁed EngelTable 4
Seizure outcomes in surveyed patients by duration of VNS therapy (follow-up time since
VNS implantation).
Duration of VNS
therapy
All eligible
patients
N (%)
All surveyed
patients
N (%)a
Favorable outcome
(N50% SR)
N (%)b
0–4 years 43 (28%) 28 (65%) 17 (74%)
5–9 years 49 (32%) 29 (59%) 19 (68%)
10–14 years 36 (23%) 22 (61%) 11 (58%)
15+ years 24 (16%) 11 (46%) 7 (70%)
p-Values NA 0.484 0.739
a Percentage of all eligible patients.
b Percentage of surveyed patientswith seizure information (0–4 years: n=23, 5–9 years:
n = 28, 10–14 years: n = 19, and 15+ years: n = 10).
Table 5
Last VNS settings for stimulation parameters.
Stimulation parameters at last VNS
setting
All eligible patients
N (%)
All surveyed patients
N (%)a
p-Values Favorable outcome (N50% SR)
N (%)b
p-Values
Output current (OC) N2 mA 32 (21%) 16 (50%) 0.232 6 (42%) 0.03
≤2 mA 120 (79%) 74 (62%) 48 (73%)
Rapid cycling (RC) N25% 22 (14%) 14 (64%) 0.648 6 (50%) 0.16
≤25% 130 (86%) 76 (59%) 48 (71%)
a Percentage of all eligible patients.
b Percentage of surveyed patients with seizure information (OC N 2: n = 14 and OC ≤ 2: n = 66; RC N 25: n = 12 and RC ≤ 25: n = 68).
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were taking signiﬁcantly fewer AEDs at the time of survey compared to
patients with unfavorable outcomes (median: 3 vs 4, p = 0.045,
Table 6). The associations of N50% SR with the psychosocial outcomes
of driving, employment, and antidepressant use were not signiﬁcant
(Table 6). Overall, 77% of this subset said VNS was worthwhile, and
this was not associated with N50% SR.
4. Discussion
This is the ﬁrst study assessing the long-term impact of VNS therapy
overmore than 15 years for epilepsy, to our knowledge, on seizure out-
comes and on selected psychosocial metrics. Our ﬁndings reveal that
adjunct VNS therapy leads to N50% SR in 68% and seizure freedom in
20% of patients. In the earlier studies, shorter-term seizure outcomes
seemed to improve with time on VNS therapy [3,17,18]. The enduring
effect of any therapy could be determined by assessment of long-term
outcomes. Seizure reduction of N50% appeared to have a stable effect
sustained for up to 15 years in the surveyed patients in our study who
had severe refractory epilepsies, in accordance with another study [8].
We assessed seizure outcomes in relation to epilepsy classiﬁcation
(Table 3) and observed that 88% of patients with temporal lobe epilepsy
achieved N50% SR. Similar ﬁndings were noted by another study [5] and
had contributed to the initial FDA approval of VNS for partial epilepsy.
Rates of N50% SR with idiopathic generalized (75%) and extratemporal
partial (72%) epilepsies that are usually associated with generalizedTable 6
Comparison of psychosocial outcomes by seizure outcomes in patients ≥18 years of age at
VNS implantation without developmental delay.
Variable Response Favorable
(N50% SR)
(N = 21)
Unfavorable
(b50% SR)
(N = 14)
p-Value
Number of AEDs at
survey
Mean ± S.D. 3.1 ± 1.6 4.1 ± 1.6 0.045
Median (range) 3 (1 to 7) 4 (2 to 8)
Driving status before
VNS
Yes 9 (45%) 3 (21%) 0.157
No 11 (55%) 11 (79%)
Driving status at survey Yes 4 (19%) 1 (7%) 0.445
No, due to seizures 14 (67%) 12 (86%)
No, due to other
reasons
3 (14%) 1 (7%)
Employment status
before VNS
Full-time 6 (29%) 3 (21%) 0.435
Part-time 6 (29%) 2 (14%)
Not employed 9 (43%) 9 (64%)
Employment status
at survey
Full-time 3 (14%) 1 (7%) 0.666
Part-time 6 (29%) 3 (21%)
Not employed 12 (57%) 10 (71%)
Use of antidepressants
before VNS
Yes 3 (14%) 1 (7%) 0.515
No 18 (86%) 13 (93%)
Use of antidepressants
at survey
Yes 8 (38%) 2 (14%) 0.127
No 13 (62%) 12 (86%)
VNS worthwhile Yes 17 (81%) 10 (71%) 0.610
No 2 (10%) 3 (21%)
Unsure 2 (10%) 1 (7%)tonic–clonic seizures were higher than that for symptomatic general-
ized epilepsy (59%) in accordance with other studies [5,19]. This
seems logical, as symptomatic generalized epilepsies are known be
characterized by multiple seizure types which are often drug-resistant.
During the course of VNS parameter settings, the output currentwas
optimized or duty cycles were adjusted to the tolerance level in all pa-
tients. Only 18% of patients (16/90) had an output current N2 mA, and
16% (14/90) had rapid cycling parameters. Although some prior studies
with shorter follow-up periods [2,20] indicated that high stimulation
lead to better SR and one study by Heck et al. [15] showed a higher in-
tensity current (N2mA) did not provide any additional beneﬁt, ourﬁnd-
ings demonstrated that a current ≤2 mA was signiﬁcantly associated
with N50% SR (p= 0.03). The XE5 study [21] revealed SR in a subgroup
of patients with increased duty cycle, whereas another study failed to
observe the same [17]. We observed that those without rapid cycling
settings were associated with a higher N50% SR rate, although this dif-
ference was not statistically signiﬁcant. This was of interest for the
AAN subcommittee [22] as well, which, in 2013, could not conclusively
determine any ideal VNS settings effective for SR. There was no signiﬁ-
cant difference in VNS complication per survey response when the set-
tings had a high output current or rapid cycling.
In our patient cohort with severe epilepsies, AEDs were usually ad-
justed. In a 2002 study by Labar [23], the continuation of AEDs during
the initial 12 months of VNS therapy was commonly noted with no
worsening of seizures with AED reduction. In the patients we surveyed,
there was an increase in the number of AEDs at the time of survey com-
pared to before VNS implantation (3.4 ± 1.5 vs 3.0 ± 1.0, p = 0.027).
Overall, the beneﬁcial effects in SR might be attributable to the comple-
mentary effect of VNS and AEDs together.
Developmental delay was noted in almost half of our patients
(44/90), and resective surgery was performed in almost a third of
our patients (28/90) prior to VNS implantation. The presence of de-
velopmental delay or prior failed epilepsy surgery did not affect the
seizure outcome of VNS therapy as noted in another study [24] as
well.
In our small sample size of patients without developmental delay,
we found that 31% drove before VNS implantation, and 14% drove at
the time of survey. Vagus nerve stimulation did not favorably affect
driving status unlike resective epilepsy surgery [25] that we document-
ed in our previous paper [12]. This is most likely due to less favorable
post-VNS seizure-free outcomes compared to resective surgery.
Our ﬁndings show that there was a decrease in full-time employ-
ment status from before VNS implantation to after at the time of survey.
This could be due to a relative aging of the surveyed patients with the
passage of time, along with the ongoing seizures due to intractability
of epilepsy.
Depression as a psychiatric comorbidity is well known in patients
with intractable epilepsy. Vagus nerve stimulation has also been FDA
approved as a treatment for severe, recurrent depression since 2005
and shown to be effective in a substantial minority of patients with re-
fractory depressive disorders for up to one [26] or 2 years [27]. In our
study, we found that when compared to before VNS initiation, almost
double the patients were being treated with antidepressants at the
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depressive symptoms due to refractory seizures or other ongoing co-
morbidities, depression as a side effect of AEDs, or better clinical recog-
nition of depression when compared to that in the past.
Overall, 81% of the patients with VNS for intractable epilepsy
thought it wasworthwhile to have the therapy irrespective of the favor-
able (N50% SR) or unfavorable seizure and psychosocial outcomes.
Much of this could be due to the very intractable nature of epilepsy in
these patients who perhaps express contentment with relative im-
provement in their seizure frequency.
There are some limitationswith this study. The survey response rate
was 59%; nonetheless, we had similar rates in our earlier study [12].
Even though patients who did and did not complete the surveys ap-
peared to be comparable on the reported patient characteristics, there
is a possibility that there may be other unmeasured factors that differ
between these two groups. A sensitivity analysis on the response of pa-
tients with N50% SR, whichwas observed to be 68% in this study, shows
that the rate would range from 36%, if all the nonsurveyed patients did
not have N50% SR, to 82%, if they all did. A second limitation of the study
is the small sample sizes for some of the comparisons, especially for the
psychosocial metrics in the adult population without developmental
delays. The reduced sample size affects the power of the statistical
tests to ﬁnd clinically meaningful differences. However, information
about thesemetrics in patients with epilepsy on VNS therapy is current-
ly not available in the literature and hence may be valuable to patients
and their health care providers. Another potential limitation of this
study is responder bias. In this study, the data collection was performed
by surveying the patients or their caregivers, with the possibility that
the responders may not have been candid with their phone responses.
During the phone surveys, to lower this potential bias, the responders
were assured that their responses would be kept conﬁdential, would
be reported in an aggregate manner with no individual identiﬁcation,
and would not affect their medical care. Cross-validation of information
with that available on EMR was done to minimize recall bias. Further-
more, retrospective study design has its own limitations, and does not
include a control group. Nevertheless, considering the heterogeneous
cohort with such difﬁcult refractory epilepsies who are not surgical can-
didates or who did not beneﬁt from epilepsy surgery, this study effec-
tively demonstrates long-term outcomes on seizure and the
psychosocial metrics in patients with epilepsy on VNS therapy.
5. Conclusion
This study shows that VNS is a well-tolerated long-term adjunctive
therapy for epilepsy, associated with >50% seizure reduction in two-
thirds of the patients and seizure freedom in one-ﬁfth of the patients.
This is theﬁrst study to demonstrate that, although there is no statistical
difference in the psychosocial metrics before and after VNS implanta-
tion for intractable epilepsy irrespective of seizure outcomes, the great
majority of patients express satisfaction with VNS therapy. Much of
this could be due to the very intractable nature of challenging epilepsies
in these patients who perhaps express satisfaction with relative seizure
control. Overall, VNS seems to provide meaningful long-term improve-
ment in outcomes when used as an adjunctive therapy for intractable
epilepsies.
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